DEVELOPMENT AND VALIDATION OF PROGNOSTIC MODEL FOR GASTRIC CANCER

胃癌预后模型的开发和验证

• 批准号: 8213747
• 负责人: Ju-Seog Lee
• 金额: $ 28.62万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-05 至 2014-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8213747
• 关键词: American Joint Committee on Cancer; Asia; Asians; Biological Markers; Biology; Cancer Center; Cancer Patient; Candidate Disease Gene; Cause of Death; Clinical; Data; Development; Diagnosis; Disease-Free Survival; Gene Expression; Gene Expression Profile; Gene Expression Profiling; Genes; Genetic Variation; Genomics; Goals; International Union Against Cancer; Malignant Neoplasms; Methods; Modeling; North America; Operative Surgical Procedures; Outcome; Pathologic; Patients; Prognostic Marker; RNA; Recurrence; Relative Risks; Risk; Screening procedure; Staging; System; Testing; Time; Validation; Virulent; base; cancer type; cohort; improved; malignant stomach neoplasm; novel; outcome forecast; prognostic; prospective; public health relevance; research study

DESCRIPTION (provided by applicant): Gastric cancer (GC) is one of the most virulent cancers in the world. Each year over 930,000 of people are diagnosed with GC and 700,000 die (2nd leading cause of death) worldwide. Patients with localized gastric cancer are most often treated surgery alone (in Asia) or surgery plus adjunct therapy (North America). This decision for treatment is empiric. There is no method to select a specific therapy or to avoid a specific one. Therefore, nearly all patients with AJCC/UICC stage II or III cancer are offered a similar treatment but their outcomes are unpredictable. We have considerable preliminary data that suggests a PCR-based practical prognostic signature (that allows us to compute a continuous "risk" score) for all pathologic stages is possible. Our main objective is to develop a PCR-based biomarker prognostic test for an "early" (= 12 months) recurrence-free survival (RFS) event for localized gastric cancer patients who undergo surgery with or without adjunct therapy. If the emerging prognostic signature has a high rate of accuracy (= 80%), alternate strategies can be developed to optimize treatment. Currently, we cannot optimize therapy and end up giving the same therapy to all patients with similar stage. Our overall goal is to validate previously identified prognostic gene signature in larger independent Asian GC patient cohort and Western GC patient cohorts, and improve the predictability of signatures by identifying more biomarkers to construct better prognostic signature and risk score. PUBLIC HEALTH RELEVANCE: The overall goal of this proposal is to develop novel prognostic risk score that can predict the likelihood of early recurrence in gastric cancer patients. Our approach will pave the way for the optimization of patient treatments according to relative risk of patients. Currently, we cannot optimize therapy and end up giving the same therapy to all patients with similar stage.

描述（由申请人提供）：胃癌（GC）是世界上最致命的癌症之一。全世界每年有超过930，000人被诊断患有GC，700，000人死亡（第二大死亡原因）。局限性胃癌患者最常接受单独手术治疗（亚洲）或手术加辅助治疗（北美）。这种治疗决定是经验性的。没有方法选择特定的治疗或避免特定的治疗。因此，几乎所有AJCC/UICC II期或III期癌症患者都接受了类似的治疗，但其结果无法预测。我们有相当多的初步数据表明，基于PCR的实际预后标志（允许我们计算连续的“风险”评分）对于所有病理阶段是可能的。我们的主要目标是开发一种基于PCR的生物标志物预后检测，用于局部胃癌患者接受手术（有或无辅助治疗）的“早期”（≥ 12个月）无复发生存（RFS）事件。如果新出现的预后标志具有高准确率（= 80%），则可以开发替代策略以优化治疗。目前，我们不能优化治疗，并最终给予相同的治疗，所有患者具有相似的阶段。我们的总体目标是在更大的独立的亚洲GC患者队列和西方GC患者队列中验证先前确定的预后基因签名，并通过确定更多的生物标志物来构建更好的预后签名和风险评分来提高签名的可预测性。 公共卫生关系：该提案的总体目标是开发新的预后风险评分，可以预测胃癌患者早期复发的可能性。我们的方法将为根据患者的相对风险优化患者治疗铺平道路。目前，我们不能优化治疗，并最终给予相同的治疗，所有患者具有相似的阶段。